Cabozanitinib in combination with atezolizumab for advanced kidney cancer

This phase Ib study reports the results of a combination of cabozantinib plus atezolizumab in people with advanced clear cell and non–clear cell renal cell carcinoma (RCC). The number and nature of side effects to the 40 mg and 60 mg dose of cabozantinib were similar. Around two thirds of patients reported side effects to […]

read more

EIKCS 2021: Combination therapies for metastatic kidney cancer: Which Approach?

The use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has increased significantly over the past 3 years. However, there are now a number of potential first-line treatments, and choosing the most suitable treatment for each individual patient can be difficult. In a presentation at the European International Kidney Cancer […]

read more

ASCO GU 2021: Cabozantinib for the treatment of kidney cancer brain metastases

Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are prevented from getting to the brain by a membrane called the blood-brain barrier. In this study, the results of which will be presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) […]

read more

ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer

The past couple of years has seen a number of combination therapies for the first-line treatment of advanced/metastatic renal cell carcinoma (RCC) become available. At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco this week, ongoing results from the phase 3 CheckMate-9ER clinical trial with the nivolumab plus cabozantinib […]

read more

Gut microbes linked with immunotherapy response in kidney cancer

A recent study published in European Urology had shown that the diversity of microbes in the gut is associated with better outcomes in people with metastatic renal cell carcinoma (RCC) who are taking immunotherapy. There are numerous bacteria and viruses in the gut, called the microbiome. This gut microbiome is increasingly linked to health and […]

read more

ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer

Results from a phase II international trial led by researchers at MD Anderson Cancer Center in America were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial showed treatment with a novel hypoxia inducible factor (HIF)-2 alpha inhibitor (MK-6482) was well tolerated and resulted in clinical responses in patients with von […]

read more

Promising efficacy and safety of seleno-L-methionine plus axitinib in advanced kidney cancer

Data from a recent phase I study of seleno-L-methionine in combination with axitinib (Inlyta) as treatment for patients with previously treated or relapsed clear cell renal cell carcinoma (ccRCC) were presented at the American Urological Association (AUA) Virtual Experience meeting over the weekend. There were 15 patients in the study with ccRCC whose disease had […]

read more

The future of immunotherapy-based combinations for metastatic kidney cancer

The past decade or so has seen the development of multiple targeted therapies for metastatic renal cell carcinoma (RCC), such as vascular endothelial growth factor (VEGF) inhibitors and inhibitors of the mammalian target of rapamycin (mTOR) pathway. Most recently, immune checkpoint inhibitors have been shown to have excellent clinical efficacy. Although patients are living longer, […]

read more

Promising early studies with pegilodecakin plus immunotherapy in pretreated kidney cancer

A recent phase 1b clinical trial investigated the use of pegilodecakin in combination with anti-PD-1 monoclonal antibodies nivolumab or pembrolizumab. The combination showed a “favourable” response in patients with non-small cell lung cancer and kidney cancer. Pegilodecakin works by stimulating the survival, proliferation and “killing” potential of CD8+ T cells, which can recognise and destroy […]

read more

ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer

Results from the JAVELIN-Renal 101 clinical trial to assess avelumab plus axitinib in untreated patients with advanced renal cell carcinoma (RCC) with sarcomatoid characteristics were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Sarcomatoid RCC is an uncommon but highly aggressive form of RCC, which tends to have […]

read more
Showing 1 to 10 of 22 results
  TOP